{"id":41486,"date":"2023-10-13T05:28:41","date_gmt":"2023-10-13T05:28:41","guid":{"rendered":"https:\/?p=41486"},"modified":"2023-10-13T05:28:41","modified_gmt":"2023-10-13T05:28:41","slug":"pfe-stock-forecast-pfizer-drops-despite-covid-19-shot-success","status":"publish","type":"post","link":"https:\/\/www.stocktargetadvisor.com\/blog\/pfe-stock-forecast-pfizer-drops-despite-covid-19-shot-success\/","title":{"rendered":"PFE Stock Forecast: Pfizer Drops Despite COVID-19 Shot Success"},"content":{"rendered":"

Pfizer (<\/span>PFE:NYE<\/span><\/a>), made headlines with its groundbreaking COVID-19 vaccine, altering the course of the pandemic. It’s clear that Pfizer continues to be a significant player in the healthcare industry. However, a closer look at the PFE stock forecast unfolds a nuanced perspective, reflecting investors’ cautious sentiment.<\/span><\/p>\n

\u00a0<\/span><\/p>\n

Impressive Uptake of Pfizer’s COVID-19 Vaccine:<\/span><\/h2>\n

Pfizer’s game-changing COVID-19 vaccine has seen substantial uptake, particularly against the XBB.1.5 subvariant of the Omicron strain. Recent data from the Department of Health and Human Services reveals that over seven million individuals have received this vaccine.<\/span><\/p>\n

Remarkably, this feat was achieved within just a month of its introduction. What sets this milestone apart is the fact that Pfizer is now venturing into the commercial market for vaccine distribution. The question that looms is how many are left to be vaccinated in the present pandemic climate.<\/span><\/p>\n

\u00a0<\/span><\/p>\n

FDA Approval for Braftovi and Mektovi Label Expansion:<\/span><\/h2>\n

Beyond its contributions to COVID-19 mitigation, Pfizer secured FDA approval for expanding the label on Braftovi and Mektovi. This expansion is aimed at catering to lung cancer patients who possess the BRAF V600E genetic mutation.<\/span><\/p>\n

While the confirmation of this mutation is a prerequisite, this green light paves the way for an expanded patient pool. Intriguingly, this approval came during an ongoing Phase 2 trial with positive results, underscoring Pfizer’s commitment to healthcare innovation.<\/span><\/p>\n

\u00a0<\/span><\/p>\n

Broader Market Sentiment:<\/span><\/h2>\n

J.P. Morgan Chase & Co.<\/span><\/a>\u00a0maintains a neutral rating, reducing the target price from USD 39 to USD 36. Moreover, the\u00a0<\/span>STA Research<\/span><\/a>\u00a0analyst lowers its target and rates it as “Underperform” at USD 30. This rating presents a bearish outlook, taking into account current circumstances.<\/span><\/p>\n

\u00a0<\/span><\/p>\n

PFE Stock Forecast:<\/span><\/h2>\n

A consensus of 12 analysts places the average target price at USD 43.60 for October 2024. While the average analyst rating is ‘Hold,’ Stock Target Advisor’s analysts are ‘Bullish.’ This stance is based on 9 positive and 3 negative signals, reflecting the market’s ongoing deliberations.<\/span><\/p>\n

<\/p>\n

\n
\n

PFE Ratings<\/a> by Stock Target Advisor<\/p>\n<\/div>\n